New stock news | Shengsheng Cold Chain plans to list in Hong Kong. The China Securities Regulatory Commission requires the company to supplement the explanation of the compliance of the equity incentive plan that has been implemented.

The China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issuance and Listing Registration (March 23, 2026 - March 27, 2026)". The International Department of the China Securities Regulatory Commission issued supplementary material requirements for 11 companies, including a requirement for Shengsheng Cold Chain to explain the compliance of the equity incentive plan it has implemented. It is reported that Shanghai Shengsheng Medical Cold Chain Technology Co., Ltd. ("Shengsheng Cold Chain") submitted its listing application to the Hong Kong Stock Exchange main board on January 13, with CICC and Sinolink (Hong Kong) as its joint sponsors. The China Securities Regulatory Commission requested Shengsheng Cold Chain to provide supplementary explanations on the following matters, request a lawyer to verify and provide clear legal opinions: 1. Please provide supplementary explanations on the specific compliance of the overseas investments and foreign exchange registration procedures of the company's overseas subsidiaries, and provide conclusive opinions on compliance. 2. Please provide supplementary explanations on the progress of the identification and management procedures of the company's state-owned shareholders. 3. Please provide supplementary explanations on the compliance of the company's implemented equity incentive plan, including specific personnel composition and appointments, the existence of any relationships between participating individuals and other shareholders, directors, supervisors, and senior management of the issuer, the fairness of pricing, agreement terms, decision-making procedures, regulatory operation, and provide clear conclusions on its legality, compliance, and the absence of any conflicts of interest. According to the prospectus, Shengsheng Cold Chain is an integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on temperature-controlled supply chain services for clinical trials and extending to commercial stage medical product temperature-controlled supply chain services, as well as the research and manufacturing of temperature-controlled equipment and materials, to create comprehensive temperature-controlled supply chain capabilities for the entire life cycle and all application scenarios. According to a report by Frost & Sullivan, based on revenue in 2024, Shengsheng Cold Chain is the top-ranked pharmaceutical and life science temperature-controlled supply chain service provider in the Chinese market, and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers.